Most ABA practice owners I talk to already believe in early diagnosis. They know the clinical case. They’ve seen what happens when a child starts intervention at two versus four. That’s not the conversation that needs to happen.

The conversation that needs to happen is about what early diagnosis means for your practice as a business, and why the practices that build diagnostic capability now are going to be the ones that grow over the next five years.

This isn’t speculation. We surveyed over 500 clinicians and educators across the U.S. in 2025 to understand what they’re experiencing on the ground. The findings tell a clear story about where the industry is headed and who’s positioned to lead.

The system is running out of capacity

You already know waitlists are long. But the survey put numbers on it that are worth paying attention to.

The bottleneck isn’t a lack of awareness. Parents are bringing concerns to their pediatricians earlier than ever. Screening tools are catching more children. The problem is what happens after the flag gets raised. There aren’t enough people and processes to evaluate them.

When we asked clinicians to identify the most time-consuming part of the evaluation process, the answer wasn’t what most people expect. It wasn’t the observation. It wasn’t scoring. It was report writing. 76.8% named it as the single biggest drain on their time.

That math doesn’t work. Not when your waitlist is six months long and your clinicians are spending more time on paperwork than on patients.

What clinicians actually want

We asked providers to rank their priorities for improving the diagnostic process. The responses tell you exactly where the market is heading.

Accuracy came in first by a wide margin. Clinicians aren’t going to trade diagnostic confidence for speed. Any tool or process change that compromises accuracy is dead on arrival.

But the second priority, faster access to intervention at 51.8%, is where it gets interesting. Providers are thinking beyond the evaluation itself. They don’t just want a faster test. They want the evaluation to be the beginning of a treatment pathway, not a standalone event that ends with a report.

Read those together and the picture is clear: the market wants accurate, fast, objective, scalable tools that work across different settings and patient populations. Subjective-only evaluation, which is what 83.3% of clinicians are still using, can’t deliver all of those at once.

The 83% gap

That number, 83.3% of clinicians not yet using digital or machine-based diagnostic tools, is probably the most important finding in the survey.

Because here’s the other side of it: 57.2% said they would adopt a validated, accurate, affordable tool that’s easy to learn and implement.

The market isn’t resistant. It’s ready. The majority of clinicians are open to new approaches. They just need the right tool to show up. One that meets the accuracy bar, fits into their workflow, and doesn’t require them to completely retool their practice.

That gap between current adoption and stated willingness is the window. And it won’t stay open forever. As more practices add diagnostic capabilities, the competitive landscape shifts. The early movers build the referral relationships. The ones who wait end up competing for what’s left.

Why this is a practice growth conversation

Here’s where I want to shift the frame. Everything above is about the clinical landscape. But if you’re running a practice, the implications are strategic.

Think about what happens today when a family calls your ABA practice and asks about a diagnostic evaluation. If you don’t offer evaluations, you do one of two things: refer them out, or tell them to get on someone else’s waitlist. Either way, you lose the relationship.

That family gets evaluated somewhere else. If they get an autism diagnosis, they likely start therapy wherever they were evaluated, or wherever that evaluator refers them. They don’t come back to the practice that told them they couldn’t help.

Now think about what happens if you can evaluate them. The family comes to you. You conduct the assessment. If the child is diagnosed, you’re already the trusted provider. You start therapy. No handoff, no waitlist, no referral leakage. The evaluation becomes the top of your own funnel.

Practices that add diagnostic services are doing three things at once: they’re creating a new billable service line (the evaluation itself), they’re capturing clients who would otherwise go to competitors, and they’re building referral relationships with pediatricians who need somewhere to send concerned families.

That last point is underappreciated. Pediatricians are desperate for a good referral pathway. If you can tell a pediatrician “send them to us, we’ll evaluate within two weeks and they can start therapy immediately if indicated,” that pediatrician is going to remember you. That relationship compounds over time.

The Early Intervention Math

The clinical evidence on early diagnosis isn’t new, but it’s worth restating in a business context because it directly affects your practice economics.

For your practice, earlier diagnosis means earlier enrollment. Earlier enrollment means more treatment hours during the period when therapy is most effective. That means better outcomes, stronger relationships with families and payers, and more referrals. It’s a virtuous cycle.

And then there’s the payer angle. The industry is moving toward value-based care. Payers want to see outcomes, not just hours billed. Practices that can demonstrate they’re identifying children early and tracking measurable progress over time are going to have a significant advantage when payer contracts get renegotiated.

What the Practices That Move First Are Doing

The practices I see making this transition are approaching it methodically. They’re not just buying a diagnostic tool and hoping for the best. They’re thinking about it as a service line with its own workflow, staffing model, and referral strategy.

They’re asking practical questions: What does the evaluation room look like? Who administers the assessment? Who interprets the results? How does the report get generated? How quickly can we schedule an evaluation after the call comes in? What are the billing codes? Which payers cover it?

These are operational questions, not clinical ones. And the answers determine whether a diagnostic capability actually generates value for the practice or just creates another bottleneck.

The technology piece matters here. When you can go from a 3-4 hour evaluation process to a 12-minute objective assessment that produces same-day results, the operational model changes completely. You can see more children with the same staff. You can reduce your waitlist from months to weeks. You can give families answers the same day they walk in the door.

That’s not just a clinical improvement. That’s a competitive advantage.

Where This Is Heading

The survey data points to an inflection. The need is growing (1 in 31 children now receive an autism diagnosis, per the latest CDC data). The workforce isn’t keeping up. The tools are ready. And over half of clinicians say they’re open to adopting them.

The practices that act on this in the next 12-18 months are going to establish themselves as the diagnostic leaders in their markets. They’ll build the referral networks, capture the client relationships, and create the outcome data that payers will increasingly require.

The ones that wait will eventually get there too, but they’ll be following, not leading.

Early diagnosis isn’t just good medicine. It’s the growth strategy that also happens to be the right thing to do.

The data in this article is drawn from a 2025 EarliPoint Health partner survey of 500+ clinicians and educators across the U.S., combined with published research on early intervention outcomes.